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Objective: The aim of our study was to evaluate the associations between arterial stiffness indexes and
immune-inflammatory markers in subjects with acute ischemic stroke with and without metabolic syndrome.
Materials/Methods: We enrolled 130 patients with acute ischemic stroke and metabolic syndrome, 127 patients
with acute ischemic stroke without metabolic syndrome and 120 control subjects without acute stroke. Applanation
tonometry was used to record the augmentation index (Aix) and pulse wave velocity (PWV). We also evaluated
plasma levels of C-reactive protein (CRP), Interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), Interleukin-6
(IL-6) and Interleukin-10 (IL-10), E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1), von Willebrand Factor (vWF) plasma levels, tissue plasminogen activator (TPA) and
plasminogen activator inhibitor-1 (PAI-1).
Results: In subjects with acute ischemic stroke and metabolic syndrome we observed higher median plasma values
of immuno-inflammatory markers. In acute ischemic stroke patients and metabolic syndrome in relation of each
TOAST subtype we observed a more significant positive correlation between PWV and immuno-inflammatory
markers.
Conclusions: Stroke subjects with acute ischemic stroke and metabolic syndrome showed a higher degree of
immuno-inflammatory and arterial stiffness indexes possibly due to metabolic background of these types of patients
that trigger a more intense immune-inflammatory activation irrespective of stroke subtype, whereas being related
to stroke subtype in subjects without metabolic syndrome.
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Arterial stiffness is increasingly recognized as an import-
ant determinant of cardiovascular risk [1,2] and may be
directly involved in the process of atherosclerosis [3]. Fac-
tors underlying increased arterial stiffness are not com-
pletely understood, but both functional and structural
alterations in the vessel wall are thought to be important.
Acute and chronic inflammation are also associated
with endothelial dysfunction [4,5]. More recently, in-
flammation has been associated with an increased risk* Correspondence: bruno.tuttolomondo@unipa.it
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article, unless otherwise stated.of cardiovascular events and the level of C-reactive pro-
tein (CRP), a marker of inflammation, predicts outcome
in patients with cardiovascular disease [6,7]. Taken to-
gether, these data suggest that inflammation may be a
key cause of cardiovascular damage.
Although there are some inconsistencies, a number of
recent studies have suggested that in a healthy population,
there may be a significant relationship between hs-CRP
and measures of arterial stiffness [8,9]. Yasmin et al. found
hs-CRP to be related to pulse wave velocity (PWV) but
not to Augmentation Index (AIx) [10]. In contrast,
Kampus et al. found hs-CRP to be independently and
significantly associated with AIx but not with the timing
of the reflected pressure wave (RT) [8]. However, inCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ger. In patients with systemic vasculitis, in which hs-
CRP levels are markedly elevated, they were positively
correlated with PWV and AIx [9].
Metabolic syndrome is a cluster of common pathologies:
abdominal obesity linked to an excess of visceral fat, insu-
lin resistance, dyslipidemia and hypertension [11]. At the
molecular level, metabolic syndrome is accompanied by
dysregulation in the expression of adipokines (cytokines
and chemokines) making metabolic syndrome an inflam-
matory condition. The molecular mechanism underlying
the relationship between metabolic syndrome and neuro-
logical disorders is not fully understood. However, it is
becoming increasingly evident that all cellular and bio-
chemical alterations observed in metabolic syndrome such
as impairment of endothelial cell function, abnormality in
essential fatty acid metabolism and alterations in lipid me-
diators along with abnormal insulin/leptin signaling may
represent a pathological bridge between metabolic syn-
drome and neurological disorders such as stroke.
The association of MetS with arterial stiffness has been
investigated in many studies [12-14]; however, most of
these studies were cross-sectional [14].
In a recent study [15] we reported that stroke patients
with metabolic syndrome, compared to stroke subjects
without metabolic syndrome, and compared to control
subjects without stroke showed a higher mean PWV.
We also showed in the same study that PWV value in
lacunar subjects with metabolic syndrome was signifi-
cantly higher compared to value observed in subjects
with lacunar stroke without metabolic syndrome. In the
same study we reported that PWV in subjects with ath-
erosclerotic and cardioembolic subtypes of stroke and
metabolic syndrome was significantly higher compared
to values observed in subjects with these stroke subtypes
and without metabolic syndrome.
Thus it’s presumable that these findings observed in
stroke patients with metabolic syndrome could be due
to inflammatory and metabolic background of subjects
with metabolic subjects that could influence acute in-
flammatory activation after an acute ischemic stroke and
arterial stiffness process.
On this basis, as an extension of this previous study and
on the same sample of patients, we analyzed plasma levels
of some immuno-inflammatory markers with the aim to
evaluate the relationships between arterial stiffness and
immune-inflammatory markers such as cytokines, selec-
tins and adhesion molecules in subjects with acute ische-
mic stroke with and without metabolic syndrome.
Materials and methods
Patient selection
Patients were considered as having metabolic syndrome
if they had ≥3 of the following components, based onmodification of the NCEP/ATP III: hypertension defined
as systolic blood pressure ≥130 mm/Hg and/or a dia-
stolic blood pressure ≥85 mm/Hg, and by history of
hypertension, raised plasma triglycerides (≥150 mg/dL
[1.7 mmol/L]), low high-density lipoprotein cholesterol
levels (≥40 mg/dL in men and ≥50 mg/dL in women),
and impaired fasting glucose defined as fasting plasma
glucose concentration ≥110 mg/dL (6.1 mmol/L), but
less than the criteria for diabetes of ≥125 mg/dL
(≥7.0 mmol/L). As a definition of obesity, we used a
body mass index ≥30 kg/m2 instead of WHR on a basis
of modification of the NCEP/ATP III [16].
We enrolled all consecutive patients with a diagnosis
of acute ischemic stroke admitted to the Internal Medi-
cine Department at the University of Palermo between
November 2009 and January 2011, and, as controls, hos-
pitalized patients with acute ischemic stroke without a
diagnosis of metabolic syndrome and hospitalized patients
without a diagnosis of acute ischemic stroke, admitted, in
the same period, to our Internal Medicine Department for
any cause other than acute cardiovascular and cerebrovas-
cular events.
Stroke was defined by focal neurological signs or
symptoms thought to be of vascular origin that persisted
for >24 hours, confirmed by brain CT and/or MRI in
baseline conditions and brain CT with contrast medium
after 48-72 hours [17].
In order to match patients with acute ischemic stroke
and controls for cardiovascular risk and previous cardio-
vascular morbidity, controls were included if they had
vascular risk factors or a history of myocardial infarction
or cerebro-vascular disease or peripheral vascular dis-
ease, but they were excluded if they had either current
or recent (within six months) cerebro-vascular disease
or one of the exclusion criteria (see above).
Cardiovascular risk factors were evaluated for both
cases and controls on the basis of the criteria shown
below. Hypercholesterolemia was defined as the pres-
ence of total cholesterol blood levels ≥200 mg/dL.
Hypertension was defined as present if subjects had
been previously diagnosed according to the World
Health Organization/International Society of Hyperten-
sion guidelines and were routinely receiving antihyper-
tensive therapy.
Patients were defined as type 2 diabetics if they had
known diabetes treated by diet, oral hypoglycemic drugs
or insulin before stroke.
Previous coronary artery disease was determined on the
basis of a history of physician-diagnosed angina, myocar-
dial infarction, or any previous revascularization proced-
ure assessed by a questionnaire.
Previous cerebro-vascular disease (TIA/ischemic stroke)
was assessed by history, specific neurologic examination
performed by specialists, and hospital or radiological (brain
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cords of definite previous stroke.
Subjects were classified as having previous peripheral ar-
tery disease (PAD) when they had a history of ABI <0.9
and/or of intermittens claudicatio or of critical limb ische-
mia or when they had undergone a peripheral arterial by-
pass or amputation.
The study protocol was approved by the Policlinico
Universitario “P. Giaccone” Ethical Committee of Pa-
lermo, and all participants gave written informed con-
sent. Every subject with ischemic stroke was matched
for age (± 3 years), sex, and cardiovascular risk factor
prevalence with one control subject.
The type of acute ischemic stroke was classified ac-
cording to the TOAST classification [18]: 1) Large Ar-
tery AtheroSclerosis (LAAS); 2) CardioEmbolic Infarct
(CEI); 3) LACunar infarct (LAC); 4) stroke of Other De-
termined Etiology (ODE); 5) stroke of UnDetermined
Etiology (UDE).
All the ischemic stroke patients underwent: medical
history with recording of potential stroke risk factors,
blood and coagulation tests, 12-lead ECG, 24 hour
electrocardiography monitoring, trans-thoracic echocar-
diography, carotid ultrasound, brain CT or MRI at ad-
mission (repeated between the third and seventh days of
stroke onset).
Neurological deficit score on admission was evaluated
by Scandinavian Stroke Scale (SSS). SSS assesses neuro-
logical deficit through an evaluation of consciousness
level, eye movement, strength in arms, hands, and legs,
orientation, language, facial weakness and gait, giving rise
to a score ranging from 58 (absence of deficit) to 0 (death).
PWV measurement
Carotid-femoral PWV was measured in the supine pos-
ition using the automatic device (SphygmoCor version
7.1) that measured the time delay between the rapid up-
stroke of the carotid and femoral artery pulse waves.
The distance between the 2 arterial points was measured
on the surface of the body using a tape measure. PWV
was calculated as the distance traveled by the arterial
pulse wave (meters) divided by the time delay between
the 2 arterial points (seconds), thus expressed as meters
per second. The "distance between the 2 arterial points"
was measured using the total distance between the ca-
rotid and femoral sites of measurement [19].
Pulse Wave analysis
Applanation tonometry was used to record radial artery
pressure waveform continuously, and mean values of ≥2
screens of pulse waves of good quality were used for
analysis. On the basis of the collected data, an averaged
radial pressure waveform was generated and a corre-
sponding aortic pressure waveform and BP calculated bythe validated transfer function (SphygmoCor version
7.1). The aortic pressure waveform was used to calculate
the AIx (difference in height between the first and sec-
ond systolic peaks expressed as a percentage of pulse
pressure (PP).Laboratory evaluation
Blood samples were obtained in the non-fasting state.
After 10 minutes of rest in the supine position, vital signs
were recorded and blood samples were collected from the
antecubital vein.
EDTA-anticoagulated peripheral blood was drawn from
each patient within 12 hours from symptom onset. Serum
and plasma were immediately separated by centrifugation
and stored in aliquots at -80°C until analysis.
We evaluated plasma levels of C-reactive protein
(CRP), Interleukin-1beta (IL-1β), tumor necrosis factor-
alpha (TNF-α), Interleukin-6 (IL-6) and Interleukin-10
(IL-10), E-selectin, P-selectin, intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), as markers of immune-inflammatory activa-
tion, von Willebrand Factor (vWF) plasma levels as a
marker of endothelial dysfunction, tissue plasminogen
activator (TPA) and plasminogen activator inhibitor-1
(PAI-1) as marker of thrombotic/ fibrinolytic pathway.
IL-1β, TNF-α, IL-6 and IL-10 and VWF antigen were
measured using a sandwich ELISA (Human IL-1β, TNF-
α, IL-6 and IL-10 Quantikine, R&D Systems (VWF
ELISA kitdurian, Instrumentation Laboratory, Milano,
Italy); VCAM-1, ICAM-1, E-selectin, P-selectin, PAI-1
and TPA-antigen were measured by commercial bioim-
munoassay (Human sICAM-1, sVCAM-I, sE-selectin
and sP-selectin Parameter, Quantikine, R&D Systems,
Gentaur AssayMax Human Plasminogen Activator
Inhibitor-1 (PAI-1) ELISA Kit, Gentaur AssayMax Tis-
sue Plasminogen Activator (TPA) ELISA Kit).
The minimum detectable concentrations for the diag-
nostic tests are: TNF alpha: 1.6 pg/mL; IL-1β: <1 pg/
mL; IL-6: <0.70 pg/mL; IL-10: >3.9 pg/mL; ICAM-1: <
0.35 ng/mL; VCAM-1: 0.6 ng/mL; E-Selectin: <0.1 ng/
mL; P-Selectin: < 0.5 ng/mL; vWF: 1.0%; TPA: 0.3 pg/
ml; PAI-1: <50 pg/ml.
Intraassay and interassay coefficients of variation were:
TNF alpha: 4.2% and 4.6%; IL-1β: 3.3% and 4.2%; IL-6:
1.6% and 3.3%; IL-10: 4.3% and 7.5%; ICAM-1: 4.8% and
6.1%; VCAM-1: 3.5% and 7.7%; E-Selectin: 4.8% and
5.7%; P-Selectin: 4.9% and 8.8%; vWF: 5% and 10%; TPA:
4.8% and 5%; PAI-1: 5.7% and 8.3%.Statistical analysis
Results are expressed as mean ± SD for continuous vari-
ables and percentages for categorical data, with P ≥ 0.05
considered significant.
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Wilk W test.
Non-normally distributed data were logarithmically
(Log10) transformed before analysis.
The relationship between immune-inflammatory
markers, PWV, AIx, and other parameters was ana-
lyzed using nonparametric methods (Spearman p cor-
relations) after correction for age and gender.
Results
We enrolled 130 patients with acute ischemic stroke and
metabolic syndrome, 127 patients with acute ischemicTable 1 Premorbid cardiovascular risk factors, clinical charact
Variable Stroke pts with metabolic
syndrome (n: 130)
Age (years) 64 (61-72.5)
M/F (n) 69/61
SBP/DBP (mm/Hg) 152±7.9/98±6.2
diabetes (n/%) 63 (48.46)
Hypertension (n/%) 66 (50.79%)
Glucose blood levels (mg/dl) 149.3 (97-186)
Cholesterol blood levels (mg/dl) 241 (189-270)
Triglyceride blood levels (mg/dl) 197.5 (149.75-210.75)
White blood cells (per mm³) 9100 (6200-11000)
Stroke subtype
• LAAS 49 (37.69)
• Lacunar 45 (34.61)
• CEI 32 (24.61)
• ODE 3 (2.3)
• UDE 1 (0.76)
AIx (%) 105 ± 3.5
PWV (m/s) 12.9 ± 3.3
SSS 27.12±16.21
IL-1-beta (pg/ml) 10 (6-11)
IL-6 (pg/ml) 12 (9-31)
TNF-α (pg/ml) 35.5 (10.25-46)
E-selectin (ng/ml) 4.05 (2.0-5.8)
P-selectin (ng/ml) 6.5 (3-8.9)
VICAM-1 (ng/ml) 18 (12.1-23)
ICAM-1 (ng/ml) 17.8 (12.2-20)
IL-10 (pg/ml) 2.05 (2-7)
vWF (ng/ml) 11 (6-15)
PAI-1 (pg/ml) 137 (99.5-155)
TPA (pg/ml) 21 (10.55-39)
CHF (n/%) 23 (17.69)
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial press
Stroke Scale score; NIHSS: National Institutes of Health Stroke Scale; Angiotensin II r
failure; TIA: transitory ischemic attack; LVH: left ventricular hypertrophy; WMHLS: wh
Demographic and history data are expressed as n° (percentage).stroke without metabolic syndrome and 120 control sub-
jects matched for age, sex, cardiovascular risk factors
and previous cardiovascular morbidity.
In patients with acute ischemic stroke and metabolic
syndrome according to the TOAST criteria, the etiology
of stroke was: large-artery atherosclerosis (LAAS) in 49
(37.69%) patients, cardioembolism (CEI) in 45 (34.61%)
patients, lacunar stroke in 32 (24.61%) patients whereas
3 (2.3%) subjects were classified as ODE and 2 UDE
(0.76%).
In patients with acute ischemic stroke without meta-
bolic syndrome, according to the TOAST criteria, theeristics and medication
Stroke pts without metabolic
syndrome (n: 127)
Controls (n: 109) P
72 (69-83.5) 69 (63-80) 0.031
60/67 54/55 0.027
147±8.9/92±3.2 141±9.8/91±2.2 <0.001
39 (30% ) 47 (41.28%) 0.263
47 (37%) 48 (44.03%) 0.301
129.1 (88-142) 102 (81.5-133.5) <0.001
222 (179-245) 210 (167-225) <0.001
157.5 (119.4-181.75) 167.5 (139.4-192.1) 0.004
8200 (7100-10500 7400 (6500-9800) <0.001
52 (40.94)
37 (29.7)
35 (27.55)
2 (1.57)
1 (0.78)
101 ± 4.1 89 ± 4.6 <0.001
11.2 ± 3.2 10.02 ± 2.29 <0.001
29.65±19 30±16.21
8 (5-16) 4 (2-5) <0.001
10.3 (7-29) 8 (3.1-12) <0.001
26 (10.55-49) 5.1 (1.1-4.3) <0.001
2.1 (1.0-3.8) 2 (1-2) <0.001
4.5 (2-6.8) 3,1 (2.1-4) 0.004
16 (10.1-20) 10 (7-15) <0.001
13.5 (12.2-20) 10.9 (12-16.1) <0.001
3.15 (2-7) 5 (2-10) 0.031
4 (3-9) 2 (1-5) 0.0001
23 (11-24) 15 ( 7-22) <0.001
55 (29-88) 11 (8-19) 0.44
20 (15.74) 15 (14.70) 0.065
ure; AIx: augmentation index; PWV: pulse wave velocity; SSS: Scandinavian
eceptor blockers (ARBs); CAD: coronary artery disease; CHF: congestive heart
ite matter hypertension lesions.
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in 52 (40.94%) patients, cardioembolism (CEI) in 37
(29.7%) patients, lacunar stroke in 35 (27.55%) patients
whereas 1 (1.57%) subjects were classified as ODE and 1
(0.78%) as UDE.
Baseline characteristics in stroke patients and in rela-
tion to each TOAST subtype are given in Tables 1 and 2.
In subjects with acute ischemic stroke and metabolic
syndrome compared to subjects with acute ischemic
stroke without metabolic syndrome and control subjects
we observed higher median plasma values of IL-1-beta
[10 (6–11) pg/ml) vs. 8 (5–16) pg/ml vs. 4 (2–5) pg/ml;Table 2 Laboratory and clinical variables and arterial stiffnes
ischemic stroke and metabolic syndrome and in patients with
Variable Lacunar p
Number With
metabolic
syndrome
(n: 49)
Without
metabolic
syndrome
(n 52)
With
metab
syndro
(n: 4
SBP/DBP (mm/Hg) 148±6.5/94±4.5 144±45/9235 0.020 146±3.4 /
Diabetes (n/%) 27 (55.10 ) 22 (42.30) 0.025 19 (42.
Hypertension (n/%) 29 (59.18 ) 28 (53.84) 0.040 19 (41.
Previous stroke (n/%) 19 (38.77) 14 (26.92) 0.010 16 (34
AIx (%) 116. 3.5 112 ± 2.8 0.030 111±3
PWV (m/sec) 14.45±2.6 12.81 ±2.1 0.030 11.2 ± 2
NIHSS 17.65±14.59 15.64 ± 8.73 0.021 22.51±1
CAD (n/%) 18 (36.73) 14 (26.92) 0.011 16 (35
Micro-albuminuria
(n/%)
21 (42.85) 17 (32.76) 0.02 17 (37
Carotid plaque (n/%) 14 (28.57) 9 (17.30 ) 0.031 16 (35
LVH (n/%) 11 (22.44) 14 (26.92) 0.021 9 (20
Previous brain infarct
at neuro-imaging
18 (36.73) 12 (23.07) 0.011 14 (30
WMHLS (n/%) 19 (38.77) 14 (26.92) 0.021 13 (28
CRP (mg/dl) 4.1 ± 2,3 3.5 ± 2.0 0.011 5.0 ± 1
IL-1-beta (pg/ml) 7 (5-11) 5.2 (3-8) 0.012 9 (5-1
IL-6 (pg/ml) 9.8 (6,5-19) 8 (6-21) 0.021 12 (6-
TNF-α (pg/ml) 29.5 (9.5-33) 23.5 (8. 5-29) 0.025 41.5 (11.2
E-selectin (ng/ml) 5.05 (1.8-5.7) 3.25 (1.7-5.7) <0.05 4.85 (1.9
P-selectin (ng/ml) 4.5 (2-6.8) 3.1 (2-4.7) 0.022 5.4 (2-
VICAM-1 (ng/ml) 19 (10.1-21) 15 (8.1-22) 0.031 17.5 (9.2
ICAM-1 (ng/ml) 20.8 (15.2-27 ) 15.8 (10.2-17 ) <0.05 18.9 (11.
IL-10 (pg/ml) 2.95 (2-7) 3.15 (2-8) 0.45 2.96 (2
vWF (ng/ml) 12 (4-19) 9 (4-16) <0.05 14 (5-
PAI-1 (pg/ml) 145 (97.5-178) 137 (98.5-149) <0.05 139 (79.4
TPA (pg/ml) 28 (16.15-39) 24 (12.15-35) 0.021 26.7 (11.
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial press
Stroke Scale score; NIHSS: National Institutes of Health Stroke Scale ; Angiotensin II
failure; LVH: left ventricular hypertrophy; WMHLS: white matter hypertension lesion
Demographic and history data are expressed as n° (percentage).p < 0.001]; IL-6 [12 (9–31) pg/ml) vs. 10.3 (7–29) pg/ml
vs. 8 (3.1-12) pg/ml; p < 0.001]; TNF-α 35.5 (10.25-46)
pg/ml) vs. 26 (10.55-49) pg/ml vs. 5.1 (1.1-4.3) pg/ml;
p < 0.001]; E-selectin [4.05 (2.0-5.8) ng/ml) vs. 2.1 (1.0-
3.8) ng/ml vs. 2 (1, 2) ng/ml; p < 0.001]; P-selectin [6.5
(3-8.9) ng/ml) vs. 4.5 (2-6.8) ng/ml vs. 3,1 (2.1-4) ng/ml;
p < 0.001]; VICAM-1 [18 (12.1-23) ng/ml) vs. 16 (10.1-
20) ng/ml vs. 10 (7–15) ng/ml; p < 0.001]; ICAM-1 [17.8
(12.2-20) ng/ml) vs. 13.5 (12.2-20) ng/ml vs. 10.9 (12-
16.1) ng/ml; p < 0.001]; vWF [17.8 (12.2-20) ng/ml) vs.
13.5 (12.2-20)ng/ml vs. 10.9 (12-16.1) ng/ml; p < 0.001];
PAI-1 [137 (99.5-155) vs. 23(11–24) ng/ml vs. 10.9 15s markers by ischemic stroke subtype in subjects with
acute ischemic stroke without metabolic syndrome
LAAS p CEI p
olic
me
5)
Without
metabolic
syndrome
(n: 37)
With
metabolic
syndrome
(n:32)
Without
metabolic
syndrome
(n:35)
93±4.5 145.5/91±2.9 0.89 144±3.8/ 90±3.1 143±2.8/90±4.1 0.71
22 ) 17 (45.94) 0.71 9 ( 28.13) 10 (28.57 ) 0.51
30 ) 20 (54.05) 0.013 14 ( 43.75) 12 (34.28) 0.011
.78) 10 (27.02) 0.041 11 (34.37) 9 (25.71) 0.027
.7 108±2.9 0.031 108±4.4 107±3.5 0.021
.31 10.4 ± 2.22 0.030 11.48 ± 1.98 11.25±2,65 0.030
6.06 19.00±12.72 0.034 25.23±8.78 22.23±8.78 0.023
.5) 12 ( 32.43) 0.71 8 (25) 8 (20) 0.07
.77) 9 (24.37) 0.03 9 ( 28.12) 7 (20) 0.045
.55) 11 ( 29.79 ) 0.023 7 (21.87) 5 (14.28 ) 0.02
) 6 (16.27 ) 0.011 10 ( 31.25) 9 (25.71) 0.03
.43) 9 ( 24.32) 0.021 9 (28.12) 7 (20) 0.02
.26) 8 (21.62) 0.032 11 (34.37) 8 (22.85 ) 0.021
.8 3.9 ± 2.1 0.018 5.8 ± 1.6 4.1 ± 1.5 0.020
2) 7.9 (4.5-12) 0.017 12 (6-17) 10.8 (6-14) 0.021
27) 10.4 (5-23.5) 0.014 13.5 (5-31) 10.2 (4-26) 0.019
5-47) 37.5 (11.6-41) 0.031 43.5 (21-58) 35.5 (20-50) <0.05
6-7.9) 2.75 (1.6-5.6) <0.05 4.15 (2.2-4.1) 3.55 (2.1-4.1) 0.011
8.0) 4.3 (2.7-6) 0.034 6.2 (3-8.9) 4.9 (2-7.5) 0.018
-20) 15 (8.2-19.8) 0.022 19 (10.1-25) 17.8 (11.1-23) 0.041
2-23) 16.9 (9.8-20) 0.028 22.6 (12.2-29) 21.3 (10-27) 0.021
-7) 3.17 (2-6) 0.52 3.2 (2-9) 23.2 (2-9) 0.39
19) 11 (5-16) <0.05 14 (6-18) 12 (6-18) 0.023
-165) 128(91.5-135) <0.05 139 (99.0-145) 109 (99.0-145) <0.05
4-31) 22 (10.5-29) 0.031 24 (12.1-47) 20 (10.1-39) 0.021
ure; AIx: augmentation index; PWV: pulse wave velocity; SSS: Scandinavian
receptor blockers (ARBs); CAD: coronary artery disease; CHF: congestive heart
s.
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(6–15) pg/ml) vs. 4 (3–9) pg/ml vs. 2 (1–5) pg/ml; p <
0.001] ( see Table 1).
Among subjects with acute ischemic stroke we ob-
served higher plasma values of CRP, IL-1β, IL-6, TNF-α,
E-Selectin, P-Selectin, ICAM-1, VCAM-1, wWF, PAI-1
in subjects with LAAS, lacunar and CEI subtype ischemic
stroke and metabolic syndrome compared to subjects with
this subtype of stroke without metabolic syndrome (see
Table 2).
Relationship between PWV and immune-inflammatory
variables
In subjects with acute ischemic stroke and metabolic
syndrome compared to subjects with acute ischemic
stroke without metabolic syndrome we observed a more
significant positive correlation for age, and gender, be-
tween PWV and CRP (r = 0.38 vs. r =0.31; p = 0.021);
TNF-α (r = 0.44 vs. r = 0.34 p < 0.05), IL1β (r = 0.39 vs. r =
0.30; p<<0.05), IL-6 (r = 0.42 vs. r = 0.35 p = 0.032), E-
selectin (r = 0.36 vs. r = 0.29; p = 0.038), P-selectin (r = 0.34
vs. r = 0.28; p = 0.041), and IL-6 (r = 0.21; P < 0.05), vWF
(r = 0.40 vs. r = 0.34; p = 0.019), PAI-1 (r = 0.37 vs. r = 0.29;
p<0.05) (see Table 3).
Relationship between AIx and and immune-inflammatory
variables
In subjects with acute ischemic stroke and metabolic
syndrome compared to subjects with acute ischemicTable 3 Correlations of PWv and Aix with immune-inflammat
Variable Pulse wave velocity
Number With metabolic
syndrome
Without metabolic
syndrome
p
(n: 49) (n: 52)
CRP 0.38 0.31 0.0
IL-1-β 0.39 0.30 <0
IL-6 0.42 0.35 0.0
TNF-α 0.44 0.34 <0
E-selectin 0.36 0.29 0.0
P-selectin 0.34 0.28 0.0
VICAM-1 0.30 0.29 0.
ICAM-1 0.30 0.29 0.
IL-10 0.19 0. 18 0.
vWF 0.40 0.34 0.0
PAI-1 0.37 0.29 <0
TPA 0.33 0.25 0.0
Coefficients (r) and p-values are calculated by the Pearson correlation mode.
SBP: systolic blood pressure ; DBP: diastolic blood pressure; MAP: mean arterial pres
Stroke Scale score; NIHSS: National Institutes of Health Stroke Scale; Angiotensin II
failure; LVH: left ventricular hypertrophy; WMHLS: white matter hypertension lesion
National Institutes of Health Stroke Scale;
Demographic and history data are expressed as n° (percentage).
Significant R and p are in bold.stroke without metabolic syndrome we observed a more
significant positive correlation for age, and gender,
between AIX and IL-6 (r = 0.33 vs. r =0.23; p = 0.022),
TNF-α (r =0.32 vs. r = 0.26; p = 0.033) and vWF (r = 0.36
vs. r =0.31; p = 0.031) (see Table 3).
Relationship Between PWV and immune-inflammatory
variables in relation to TOAST subtype
Among subjects with lacunar subtype and metabolic
syndrome, PWV (after correction for age and gender)
was more significantly and positively related to CRP, IL-
1β, IL-6, TNF-α, vWF and PAI-1 (see Table 4) compared
to subjects without metabolic syndrome and the same
subtype of stroke.
In subjects with stroke classified as LAAS and meta-
bolic syndrome, PWV was more significantly and posi-
tively related to CRP, IL-1β, IL-6, TNF-α, vWF and PAI-
1 (see Table 4) compared to subjects without metabolic
syndrome and the same subtype of stroke.
In subjects with CEI subtype and metabolic syndrome,
PWV was more significantly and positively related to
vWF but not with TNF-α, CRP, IL-6, IL-1β and PAI-1
(see Table 4) compared to subjects without metabolic
syndrome and the same subtype of stroke.
Relationship between AIx and immune-inflammatory vari-
ables in relation to TOAST subtype
Among subjects with Lacunar subtype, AIx was more
positively and significantly correlated (after correction forory variables
Augmentation Index
With metabolic
syndrome
Without metabolic
syndrome p
(n: 45) (n: 37)
21 0.27 0.26 0.73
.05 0.21 0.23 0.66
32 0.33 0.23 0.022
.05 0.32 0.26 0.033
38 0.19 0.21 0.56
41 0.18 0.16 0.44
70 0.20 0.22 0.66
81 0.22 0.24 0.63
42 0.22 0. 23 0.56
19 0.36 0.31 0.031
.05 0.18 0.15 0.77
22 0.20 0.21 0.69
sure; AIx: augmentation index; PWV: pulse wave velocity; SSS: Scandinavian
receptor blockers (ARBs); CAD: coronary artery disease ; CHF: congestive heart
s; TIA: transitory ischemic attack; SSS: Scandinavian Stroke Scale score; NIHSS:
Table 4 Correlations of PWv with clinical variables and cardiovascular risk factors in relation to TOAST stroke subtype
Lacunar LAAS CEI
Variable Pulse wave velocity (PWv) Pulse wave velocity (PWv) Pulse wave velocity (PWv)
With metabolic
syndrome (n: 49)
Without
metabolic
syndrome (n 52)
p With metabolic
syndrome
(n: 45)
Without
metabolic
syndrome (n: 37)
p With metabolic
syndrome (n:32)
Without
metabolic
syndrome (n:35)
p
CRP 0.32 0.27 0.031 0.38 0.32 0.041 0.29 0.28 0.63
IL-1-β 0.34 0.29 0.029 0.37 0.29 <0.05 0.31 0.28 0.75
IL-6 0.33 0.28 0.030 0.35 0.32 0.041 0.29 0.28 0.63
TNF-α 0.32 0.27 0.028 0.31 0.29 <0.05 0.31 0.28 0.75
E-selectin 0.32 0.23 0.65 0.31 0.23 0.041 0.19 0.20 0.61
P-selectin 0.34 0.27 0.071 0.29 0.24 <0.05 0.17 0.21 0.37
VICAM-1 0.33 0.29 0.060 0.36 0.26 0.041 0.19 0.20 0.61
ICAM-1 0.34 0.26 0.072 0.38 0.33 0.041 0.17 0.21 0.37
IL-10 0.20 0.22 0.56 0.21 0.23 0.66 0.23 0.25 0.57
vWF 0.37 0.31 0.023 0.41 0.34 <0.05 0.40 0.31 <0.05
PAI-1 0.31 0.22 0.043 0.34 0.23 0.041 0.19 0.20 0.61
TPA 0.29 0.26 0.55 0.26 0.24 0.75 0.20 0.21 0.37
Coefficients (r) and p-values are calculated by the Pearson correlation mode.
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; AIx: augmentation index; PWV: pulse wave velocity; SSS: Scandinavian
Stroke Scale score; NIHSS: National Institutes of Health Stroke Scale; Angiotensin II receptor blockers (ARBs); CAD: coronary artery disease; CHF: congestive heart
failure; LVH: left ventricular hypertrophy; WMHLS: white matter hypertension lesions.
Demographic and history data are expressed as n° (percentage).
Significant R and p are in bold.
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http://www.dmsjournal.com/content/6/1/28age and gender) only to TNF-α, IL-1β and vWF compared
to subjects without metabolic syndrome; in subjects with
LAAS subtype and metabolic syndrome we observed a
more significant and positive relationship between AIx
and IL-6. vWF and TNF-α compared to subjects without
metabolic syndrome; in CEI group with metabolic syn-
drome IL-6, TNF-α and v-WF were more positively and
significantly related to AIx compared to subjects without
metabolic syndrome (see Table 5).
Discussion
Our main findings were that patients with acute ische-
mic stroke and metabolic syndrome had both increased
inflammatory markers and arterial stiffness indexes,
compared to control subjects with acute ischemic stroke
without metabolic syndrome.
This is the first study, to the best of our knowledge, to
show in patients with acute ischemic stroke and meta-
bolic syndrome that circulating levels of some immune-
inflammatory markers such as CRP, IL-6, IL-1 β, TNF-α
and VWF are more significantly correlated to PWV and
wave reflection compared to subjects without metabolic
syndrome.
The existence of a strong association between the
presence of MetS and arterial stiffness has been shown
in many cross-sectional studies [20,21].
Inflammation is an important component of meta-
bolic syndrome (MetS) which could be the link betweenthe metabolic and cardiovascular consequences of this
condition. Low-grade systemic inflammation, elevated
leptin concentration and low adiponectin level are de-
scribed in very young obese children, correlating with a
range of variables of metabolic syndrome. Inflammation
and adipocytokines can play an important role in the
etiology of metabolic syndrome [21].
Results from some studies [20,21] show that adiponec-
tin concentrations are reduced with increased adiposity,
while others show that TNF-α, IL-6, resistin and CRP
concentrations may be elevated with increased adiposity.
A possible link exist between decreased adiponectin with
increased insulin resistance, while some evidence links
increased TNF-α and resistin with increased insulin re-
sistance Another study relate higher blood pressures to
decreased adiponectin, increased TNF-α, and CRP con-
centrations [22].
Our findings, reporting higher plasma values of
immune-inflammatory variables in subjects with acute
ischemic stroke and metabolic syndrome, and more sig-
nificant correlations between these immune-inflammatory
variables and arterial stiffness markers in subjects with
metabolic syndrome, underlines the role of inflammation
in the vascular complications of metabolic syndrome.
Our findings show that both aortic stiffness and wave
reflection are more related to the degree of systemic in-
flammation in stroke subjects with metabolic syndrome,
suggesting that circulating inflammation mediators such as
Table 5 Correlations of AIx with clinical variables and cardiovascular risk factors in relation to TOAST stroke subtype
Lacunar LAAS CEI
Variable Augmentation Index (AIx) p Augmentation Index (AIx) p Augmentation Index (AIx) p
With metabolic
syndrome
(n: 45)
Without metabolic
syndrome
(n: 37)
0 With metabolic
syndrome (n: 45)
Without
metabolic
syndrome (n: 37)
With metabolic
syndrome
(n:32)
Without
metabolic
syndrome (n:35)
CRP 0.24 0.26 0.73 0.27 0.26 0.81 0.20 0.21 0.73
IL-1-β 0.21 0.22 0.60 0.24 0.25 0.66 0.20 0.22 0.56
IL-6 0.31 0.25 0.026 0.34 0.226 0.011 0.33 0.23 0.022
TNF-α 0.33 0.27 0.022 0.32 0.26 0.033 0.32 0.26 0.033
E-
selectin
0.20 0.27 0.56 0.19 0.21 0.56 0.19 0.21 0.56
P-
selectin
0.19 0.15 0.33 0.18 0.16 0.44 0.18 0.16 0.44
VICAM-1 0.21 0.22 0.66 0.22 0.21 0.66 0.20 0.22 0.66
ICAM-1 0.22 0.24 0.63 0.20 0.24 0.63 0.22 0.24 0.63
IL-10 0.22 0. 23 0.56 0.22 0. 23 0.56 0.22 0. 23 0.56
vWF 0.36 0.30 0.020 0.33 0.27 0.029 0.36 0.32 0.018
PAI-1 0.19 0.14 0.64 0.16 0.14 0.77 0.18 0.15 0.77
TPA 0.22 0.25 0.77 0.20 0.21 0.69 0.20 0.21 0.69
<0.05
0.033
Coefficients (r) and p-values are calculated by the Pearson correlation mode.
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; AIx: augmentation index; PWV: pulse wave velocity; SSS: Scandinavian
Stroke Scale score; NIHSS: National Institutes of Health Stroke Scale ; Angiotensin II receptor blockers (ARBs); CAD: coronary artery disease; CHF: congestive heart
failure; LVH: left ventricular hypertrophy; WMHLS: white matter hypertension lesions. Demographic and history data are expressed as n° (percentage). Significant R
and p are in bold.
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http://www.dmsjournal.com/content/6/1/28CRP and some pro-inflammatory cytokines can influence
the stiffness of vessels distant to those involved in the dis-
ease process itself.
This finding also emphasizes the systemic nature of
the inflammatory response both in the atherosclerosis
process and after acute ischemic stroke, encompassing
biochemical and hemodynamic parameters. Cytokine
plasma levels in their turn also influence vascular vul-
nerability to the inflammatory response and decreased
production of the endogenous vasodilator nitric oxide
(NO) [23], and it has been demonstrated that inhibition
of basal NO synthesis increases aortic AIx75 and vel-
ocity in vivo [23].
An immune-inflammatory cascade occurs after an
acute ischemic stroke [22,24], so, on this basis, cytokine
levels that we reported and measured 72 hr from symp-
tom onset, express an acute rise in these inflammatory
markers. What is the relationship between acute high
levels of cytokines and arterial stiffness indexes in stroke
patients in relation to the presence of metabolic syn-
drome? Does metabolic syndrome trigger a higher de-
gree of hyper-acute inflammatory state after ischemic
stroke directly causing an increase of arterial stiffness?
Or in stroke-prone patients with a chronic inflammatory
activation due to their metabolic background (insulinresistance, adipocite dysfunction) exacerbated by acute
stressor events such an acute cerebrovascular event, does
inflammation represent the pathogenic basis of higher ar-
terial stiffness indexes levels in patients with acute ische-
mic stroke and metabolic syndrome compared to stroke
patients without metabolic syndrome?
It’s difficult to answer, maybe the peculiar metabolic
and inflammatory background of metabolic syndrome
may explain the observed relationship between immune-
inflammatory markers, arterial stiffness indexes and acute
ischemic stroke in metabolic syndrome patients.
In diabetes and metabolic syndrome exists a complex
interrelationship of various inflammatory variables with
metabolic disorders and their effect on the cardiovascular
system. A simplified explanation can be that inflammation
increases insulin resistance, which in turn leads to obesity
while perpetuating diabetes, high blood pressure, pro-
thrombotic state and dyslipidaemia [25]. Some studies
[26,27] have produced data suggesting an interplay be-
tween hormones, cytokines and resistin. Insulin resistance
represents a common metabolic abnormality leading to
cardiovascular disease and cerebrovascular complications.
As several cytokines are also produced by adipose tissue
[28] it was postulated that an “adipo-vascular” axis [29]
may contribute to the increased risk of cardiovascular
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http://www.dmsjournal.com/content/6/1/28events in patients with metabolic syndrome. In patients
with metabolic syndrome this “adipo-vascular axis" ex-
presses itself in lower plasma levels of adiponectin and
higher plasma levels of IL-6 that could be linked to the de-
velopment of arterial stiffness and to the pathogenesis of
ischemic stroke through microvascular and inflammatory
mechanisms. Inflammation has been emphasized as a
critical factor in the pathogenesis and destabilization of
atherosclerotic lesions [30]. Early in the course of diabetes
and metabolic syndrome intracellular hyperglycemia due
to insulin resistance causes changes in blood flow and in-
creased vascular permeability. This reflects decreased ac-
tivity of nitric oxide, and increased activity of angiotensin
II and endothelin-1 [31,32]. Angiotensin II produces acute
vasoconstriction, leading to an increase in blood pressure.
Endothelin-1 is also an important regulator of vascular
tone and has been implicated in the pathogenesis of ath-
erosclerosis. In addition, abnormalities of extracellular
matrix contribute to an irreversible increase in vascular
permeability. Hyperglycemia itself leads not only to de-
creased endothelial production of nitric oxide, which
represents an anti-atherogenic molecule, but also to in-
creased production of a potent inhibitor of fibrinolysis,
namely plasminogen activator inhibitor 1 (PAI-1) [33].
Circulating inflammatory markers, such as hs-CRP, are
known to be associated with cardiovascular disease and
are useful for risk stratification of patients with cardio-
vascular disease [34,35]. However, circulating inflamma-
tory markers cannot provide information on the vascular
inflammation of local individual vascular lesions.
In subjects with acute ischemic stroke and metabolic
syndrome we observed higher plasma values of immune-
inflammatory markers in subjects with LAAS, lacunar and
CEI subtype of ischemic stroke and metabolic syndrome
compared to subjects with these subtypes of stroke without
metabolic syndrome. This finding appears especially inter-
esting in relation to the previous findings by our group
[36-40] showing a higher degree of immune-inflammatory
activation of the acute phase of stroke only in CEI subtype
of stroke, whereas in patients with acute ischemic stroke
and metabolic syndrome these three subtypes of stroke are
characterized by a higher degree of immune-inflammatory
activation compared to patients with acute ischemic stroke
and without metabolic syndrome. It is as if metabolic
background could trigger a high inflammatory cascade ir-
respective of stroke subtype and of its pathogenesis.
Nevertheless, it’s possible to obtain an answer to the
question about the relationship between inflammation
markers and arterial stiffness indexes in acute ischemic
stroke in subjects with metabolic syndrome by evaluat-
ing our findings of some significant correlations at
intra-group analysis in each TOAST subtype between ar-
terial stiffness indexes and immune-inflammatory markers.
We observed a higher correlation between immune-inflammatory variables and arterial stiffness indexes in sub-
jects with acute ischemic stroke and metabolic syndrome,
whereas a subtype oriented analysis showed a higher
relationship between inflammatory variables and PWV in
LAAS, lacunar and CEI subtypes of stroke. In a previous
study [36] by our group cardioembolic stroke appears as
the “less atherosclerotic” among each diagnostic subtype of
stroke, reporting the correlation of PWV only with CRP
and vWF. In our subjects with acute ischemic stroke and
metabolic syndrome, metabolic background and inflamma-
tory pathways of these types of patients trigger a more
intense immune-inflammatory activation irrespective of
stroke subtype and this finding could appear original owing
to the fact that no study to our knowledge evaluated in-
flammatory degree in patients with metabolic syndrome
and an acute ischemic event such as ischemic stroke.
In conclusion, the results of our study support the view
that patients with metabolic syndrome and acute ischemic
stroke have a higher degree of immune-inflammatory
markers strictly related to values of arterial stiffness in-
dexes compared to stroke controls without metabolic syn-
drome and independently of stroke subtypes.
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